Present and future therapeutic strategies in non-alcoholic fatty liver disease

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 9, 2007, Pages 1231-1249

  Calamita, Giuseppe ^a   Portincasa, Piero ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Antioxidant; Aquaglyceroporin; Aquaporin; Fatty liver; Glitazone; Insulin resistance; Liver steatosis; Metabolic syndrome; Oxidative stress; Probiotic; Sibutramine

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AQUAGLYCEROPORIN; ASPARTATE AMINOTRANSFERASE; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETAINE; BEZAFIBRATE; CLOFIBRATE; GEMFIBROZIL; INSULIN; LIPID; LOSARTAN; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; PROBIOTIC AGENT; PROBUCOL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALCOHOL CONSUMPTION; BARIATRIC SURGERY; BIFIDOBACTERIUM; CALORIC RESTRICTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; ELASTOGRAPHY; ENVIRONMENTAL FACTOR; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEREDITY; HUMAN; INSULIN RESISTANCE; LACTOBACILLUS; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; STREPTOCOCCUS THERMOPHILUS; WEIGHT REDUCTION; ANIMAL; FATTY LIVER; GENETICS; GENOMICS; GENOTYPE;

ANIMALS; FATTY LIVER; GENOMICS; GENOTYPE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 34548819916     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.9.1231     Document Type: Review

References (235)

1. LUDWIG J, VIGGIANO TR, MCGILL DB, OH BJ: Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. (1980) 55:434-438.
2. NEUSCHWANDER-TETRI BA, BACON BR: Non-alcoholic steatohepatitis. Med. Clin. North Am. (1996) 80:1147-1166.
3. LOGUERCIO C, DE GIROLAMO V, DE SIO I et al.: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. (2001) 35:568-574.
4. LOGUERCIO C, DE SIMONE T, D'AURIA MV et al.: Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian association for the study of the liver. Dig. Liver Dis. (2004) 36:398-405
5. SILVERMAN JF, O'BRIEN KF, LONG S et al.: Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. (1990) 85:1349-1355.
6. DAM-LARSEN S, FRANZMANN M, ANDERSEN IB et al.: Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 53:750-755.
7. CORTEZ-PINTO H, BAPTISTA A, CAMILO ME, DE MOURA MC: Nonalcoholic steatohepatitis - a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig. Dis. Sci. (2003) 48:1909-1913.
8. THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III). FINAL REPORT: Circulation (2002) 106:3143-3421.
9. FAN JG, ZHU J, LI XJ et al.: Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. (2005) 43:508-514.
10. MARCHESINI G, BUGIANESI E, FORLANI G et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 37:917-923.
11. SHULMAN AI, MANGELSDORF DJ: Retinoid × receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. (2005) 353:604-615.
12. HASLAM DW, JAMES WP: Obesity. Lancet (2005) 366:1197-1209.
13. DAY CP, JAMES OF: Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 114:842-845.
14. FALCK-YTTER Y, YOUNOSSI ZM, MARCHESINI G, MCCULLOUGH AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. (2001) 21:17-26.
15. JAMES OF, DAY CP: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol. (1998) 29:495-501.
16. MCLAREN DS, BITAR JG, NASSAR VH: Protein-calorie malnutrition and the liver. Prog. Liver Dis. (1972) 4:527-536.
17. VIGANO M, VERGANI A, TROMBINI P, PALEARI F, PIPERNO A: Insulin resistance influence iron metabolism and hepatic steatosis in Type II diabetes. Gastroenterology (2000) 118:986-987.
18. YANG SQ, LIN HZ, LANE MD, CLEMENS M, DIEHL AM: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA (1997) 94:2557-2562.
19. RUBBIA-BRANDT L, LEANDRO G, SPAHR L et al.: Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology (2001) 39:119-124.
20. SOKOL RJ, TWEDT D, MCKIM JM Jr et al.: Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology (1994) 107:1788-1798.
21. PLOEG RJ, D'ALESSANDRO AM, KNECHTLE SJ et al.: Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation (1993) 55:807-813.
22. MATTEONI CA, YOUNOSSI ZM, GRAMLICH T, BOPARAI N, LIU YC, MCCULLOUGH AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 116: 1413-1419.
23. SANYAL AJ, CAMPBELL-SARGENT C, MIRSHAHI F et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 120:1183-1192.
24. TILG H, DIEHL AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. (2000) 343:1467-1476.
25. ABIRU S, MIGITA K, MAEDA Y et al.: Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int. (2006) 26: 39-45.
26. KUGELMAS M, HILL DB, VIVIAN B, MARSANO L, MCLAIN CJ: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 38:413-419.
27. WELLEN KE, HOTAMISLIGIL GS: Inflammation, stress, and diabetes. J. Clin. Invest. (2005) 115:1111-1119.
28. SHOELSON SE, HERRERO L, NAAZ A: Obesity, inflammation, and insulin resistance. Gastroenterology (2007) 132:2169-2180.
29. BROWNING JD, HORTON JD: Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. (2004) 114:147-152.
30. STEWART SF, VIDALI M, DAY CP, ALBANO E, JONES DE: Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology (2004) 39:197-203.
31. PALMIERI VO, GRATTAGLIANO I, PORTINCASA P, PALASCIANO G: Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J. Nutr. (2006) 136:3022-3026.
32. BIANCHI G, MARCHESINI G, ZOLI M, BUGIANESI E, FABBRI A, PISI E: Prognostic significance of diabetes in patients with cirrhosis. Hepatology (1994) 20:119-125.
33. PESSAYRE D, BERSON A, FROMENTY B, MANSOURI A: Mitochondria in steatohepatitis. Semin. Liver Dis. (2001) 21:57-69.
34. ROBERTSON G, LECLERCQ I, FARRELL GC: Non-alcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 281:G1135-G1139.
35. ENRIQUEZ A, LECLERCQ I, FARRELL GC, ROBERTSON G: Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem. Biophys. Res. Commun. (1999) 255:300-306.
36. LECLERCQ IA, FIELD J, ENRIQUEZ A, FARRELL GC, ROBERTSON GR: Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem. Biophys. Res. Commun. (2000) 268:337-344.
37. WELTMAN MD, FARRELL GC, HALL P, INGELMAN-SUNDBERG M, LIDDLE C: Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology (1998) 27:128-133.
38. CHOI S, DIEHL AM: Role of inflammation in non-alcoholic steatohepatitis. Curr. Opin. Gastroenterol. (2005) 21:702-707.
39. CHITTURI S, FARRELL GC: Etiopathogenesis of non-alcoholic steatohepatitis. Semin. Liver Dis. (2001) 21:27-41.
40. DAY CP: From fat to inflammation. Gastroenterology (2006) 130:207-210.
41. WAJCHENBERG BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. (2000) 21:697-738.
42. GARRUTI G, GIUSTI V, NUSSBERGER J et al.: Expression and secretion of atrial natriuretic peptide in human adipose tissue and pre-adipocytes. Obes. Res. (2007) 15 (ahead of publication).
43. JENSEN MD, HAYMOND MW, RIZZA RA, CRYER PE, MILES JM: Influence of body fat distribution on free fatty acid metabolism in obesity. J. Clin. Invest. (1989) 83:1168-1173.
44. PAREKH S, ANANIA FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology (2007) 132:2191-2207.
45. TRAYHURN P: Adipose tissue in obesity - an inflammatory issue. Endocrinology (2005) 146:1003-1005.
46. TRAYHURN P, WOOD IS: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. (2005) 33:1078-1081.
47. KAHN BB, FLIER JS: Obesity and insulin resistance. J. Clin. Invest. (2000) 106:473-481.
48. FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763-770.
49. BARZILAI N, WANG J, MASSILON D, VUGUIN P, HAWKINS M, ROSSETTI L: Leptin selectively decreases visceral adiposity and enhances insulin action. J. Clin. Invest. (1997) 100:3105-3110.
50. REDDY JK: Non-alcoholic steatosis and steatohepatitis. III. Peroxisomal β-oxidation, PPAR a, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 281:G1333-G1339.
51. PEREZ-CARRERAS M, DEL HOYO P, MARTIN MA et al.: Defective hepatic mitochondrial respiratory chain in patients with non-alcoholic steatohepatitis. Hepatology (2003) 38:999-1007.
52. FELDSTEIN AE, CANBAY A, ANGULO P et al.: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 125:437-443.
53. OSTERREICHER CH, STICKEL F, BRENNER DA: Genomics of liver fibrosis and cirrhosis. Semin. Liver Dis. (2007) 27:28-43.
54. WILLNER IR, WATERS B, PATIL SR, REUBEN A, MORELLI J, RIELY CA: Ninety patients with non-alcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am. J. Gastroenterol. (2001) 96:2957-2961.
55. STRUBEN VM, HESPENHEIDE EE, CALDWELL SH: Non-alcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. (2000) 108:9-13.
56. DIXON JB, BHATHAL PS, JONSSON JR, DIXON AF, POWELL EE, O'BRIEN PE: Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J. Hepatol. (2003) 39:967-971.
57. OSTERREICHER CH, BRENNER D: The genetics of nonalcoholic fatty liver disease. Ann. Hepatology (2007) 6:83-88.
58. REID AE: Non-alcoholic fatty liver disease. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. Sleisenger MH & Fordtran JS (Eds), Philadelphia: WB Saunders (2006):1793-1805.
59. CHITTURI S, ABEYGUNASEKERA S, FARRELL GC et al.: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 35:373-379.
60. DAVIES RJ, SAVERYMUTTU SH, FALLOWFIELD M, JOSEPH AL: Paradoxical lack of ultrasound attenuation with gross fatty change in the liver. Clin. Radiol. (1991) 43:393-396.
61. AUBE C, OBERTI F, KORALI N et al.: Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J. Hepatol. (1999) 30:472-478.
62. JOY D, THAVA VR, SCOTT BB: Diagnosis of fatty liver disease: is biopsy necessary? Eur. J. Gastroenterol Hepatol. (2003) 15:539-543.
63. PORTINCASA P, GRATTAGLIANO I, LAUTERBURG BH, PALMIERI VO, PALASCIANO G, STELLAARD F: Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin. Sci. (Lond.) (2006) 111:135-143.
64. CURRY MP, AFDHAL NH: Non-invasive assessment of hepatic fibrosis. UpToDate (2007) v.15.2:1-5.
65. WAI CT, GREENSON JK, FONTANA RJ et al.: A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 38:518-526.
66. IMBERT-BISMUT F, RATZIU V, PIERONI L, CHARLOTTE F, BENHAMOU Y, POYNARD T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 357:1069-1075.
67. HALFON P, BACQ Y, DE MURET A, et al.: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J. Hepatol. (2007) 46:395-402.
68. ROSENBERG WM, VOELKER M, THIEL R et al.: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 127:1704-1713.
69. SEBASTIANI G, VARIO A, GUIDO M et al.: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J. Hepatol. (2006) 44:686-693.
70. PARKES J, GUHA IN, RODERICK P, ROSENBERG W: Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J. Hepatol. (2006) 44:462-474.
71. LAINE F, BENDAVID C, MOIRAND R et al.: Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology (2004) 39:1639-1646.
72. LIANG RJ, WANG HH, LEE WJ, LIEW PL, LIN JT, WU MS: Diagnostic value of ultrasonographic examination for non-alcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes. Surg. (2007) 17:45-56.
73. SANDRIN L, FOURQUET B, HASQUENOPH JM et al.: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. (2003) 29:1705-1713.
74. FOUCHER J, CHANTELOUP E, VERGNIOL J et al.: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut (2006) 55:403-408.
75. KETTANEH A, MARCELLIN P, DOUVIN C et al.: Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J. Hepatol. (2007) 46:628-634.
76. GANNE-CARRIE N, ZIOL M, DE LEDINGHEN V et al.: Accuracy of liver stiffness measurement fur the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006)44:1511-1517.
77. SPYCHER C, ZIMMERMANN A, REICHEN J: The diagnostic value of liver biopsy. BMC Gastroenterol. (2001) 1:12.
78. KLEINER DE, BRUNT EM, VAN NATTA M et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 41:1313-1321.
79. RATZIU V, GIRAL P, CHARLOTTE F et al.: Liver fibrosis in overweight patients. Gastroenterology (2000) 118:1117-1123.
80. ADAMS LA, SANDERSON S, LINDOR KD, ANGULO P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. (2005) 42:132-138.
81. FASSIO E, ALVAREZ E, DOMINGUEZ N, LANDEIRA G, LONGO C: Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology (2004) 40:820-826.
82. YOUNOSSI ZM, GRAMLICH T, MATTEONI CA, BOPARAI N, MCCULLOUGH AJ: Nonalcoholic fatty liver disease in patients with Type 2 diabetes. Clin. Gastroenterol. Hepatol. (2004) 2:262-265.
83. GRUNDY SM: Does the metabolic syndrome exist? Diabetes Care (2006) 29:1689-1692.
84. LIRUSSI F, AZZALINI L, ORANDO S, ORLANDO R, ANGELICO F: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (2007):CD004996.
85. ORLANDO R, AZZALINI L, ORANDO S, LIRUSSI F: Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (2007):CD005160.
86. ANGELICO F, BURATTIN M, ALESSANDRI C, DEL BM, LIRUSSI F: Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst. Rev. (2007):CD005166.
87. LIRUSSI F, MASTROPASQUA E, ORANDO S, ORLANDO R: Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (2007):CD005165.
88. PORTINCASA P, GRATTAGLIANO I, PALMIERI VO, PALASCIANO G: Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem. (2005) 38:203-217.
89. PORTINCASA P, GRATTAGLIANO I, PALMIERI VO, PALASCIANO G: Current pharmacological treatment of nonalcoholic fatty liver. Curr. Med. Chem. (2006) 13:2889-2900.
90. DIXON JB, BHATHAL PS, HUGHES NR, O'BRIEN PE: Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology (2004) 39:1647-1654.
91. SOLGA S, ALKHURAISHE AR, CLARK JM et al.: Dietary composition and non-alcoholic fatty liver disease. Dig Dis. Sci. (2004) 49:1578-1583.
92. OKITA M, HAYASHI M, SASAGAWA T et al.: Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition (2001) 17:542-547.
93. DE KNEGT RJ: Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand. J. Gastroenterol. Suppl. (2001):88-92.
94. ANDERSEN T, GLUUD C, FRANZMANN MB, CHRISTOFFERSEN P: Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. (1991) 12:224-229.
95. WEINER R, GUTBERLET H, BOCKHORN H: Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. Obes. Surg. (1999) 9:261-264.
96. KLEIN S, MITTENDORFER B, EAGON JC et al.: Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 130:1564-1572.
97. STERN L, IQBAL N, SESHADRI P et al.: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann. Intern. Med. (2004) 140:778-785.
98. LUQUE CA, REY JA: Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. (1999) 33:968-978.
99. FILIPPATOS TD, KIORTSIS DN, LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF MS: A review of the metabolic effects of sibutramine. Curr. Med. Res. Opin. (2005) 21:457-468.
100. LI Z, MAGLIONE M, TU W et al.: Meta-analysis: pharmacologic treatment of obesity Ann. Intern. Med. (2005) 142:532-546.
101. TAMBASCIA MA, GELONEZE B, REPETTO EM, GELONEZE SR, PICOLO M, MAGRO DO: Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes. Metab. (2003) 5:338-344.
102. VALSAMAKIS G, MCTERNAN PG, CHETTY R et al.: Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism (2004) 53:430-434.
103. SABUNCU T, NAZLIGUL Y, KARAOGLANOGLU M, UCAR E, KILIC FB: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom. J. Gastroenterol. (2003) 12:189-192.
104. TORGERSON JS, HAUPTMAN J, BOLDRIN MN, SJOSTROM L: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care (2004) 27:155-161.
105. HARRISON SA, FINCKE C, HELINSKI D, TORGERSON S, HAYASHI P: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment. Pharmacol. Ther. (2004) 20:623-628.
106. HATZITOLIOS A, SAVOPOULOS C, LAZARAKI G et al.: Efficacy of ω-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J. Gastroenterol. (2004) 23:131-134.
107. RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
108. LIU YL, CONNOLEY IP, WILSON CA, STOCK MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. (Lond.) (2005) 29:183-187.
109. BENSAID M, GARY-BOBO M, ESCLANGON A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63:908-914.
110. BOYD ST, FREMMING BA: Rimonabant - a selective CB1 antagonist. Ann. Pharmacother. (2005) 39:684-690.
111. DESPRES JP, GOLAY A, SJOSTROM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353:2121-2134.
112. VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
113. FERRANNINI E, BARRETT EJ, BEVILACQUA S, DEFRONZO RA: Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. (1983) 72:1737-1747.
114. LARSSON NG, CLAYTON DA: Molecular genetic aspects of human mitochondrial disorders. Annu. Rev. Genet. (1995) 29:151-178.
115. LIN HZ, YANG SQ CHUCKAREE C, KUHAJDA F, RONNET G, DIEHL AM: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. (2000) 6:998-1003.
116. LOMBES A, MENDELL JR, NAKASE H et al.: Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology biochemistry, and molecular genetics. Ann. Neurol. (1989) 26:20-33.
117. BUGIANESI E, GENTILCORE E, MANINI R et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. (2005) 100:1082-1090.
118. UYGUN A, KADAYIFCI A, ISIK AT et al.: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. (2004) 19:537-544.
119. SANYAL AJ, MOFRAD PS, CONTOS MJ et al.: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. (2004) 2:1107-1115.
120. BELFORT R, HARRISON SA, BROWN K et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. (2006) 355:2297-2307.
121. KIRPICHNIKOV D, MCFARLANE SI, SOWERS JR: Metformin: an update. Ann. Intern. Med. (2002) 137:25-33.
122. MARCHESINI G, BRIZI M, BIANCHI G, TOMASSETTI S, ZOLI M, MELCHIONDA N: Metformin in non-alcoholic steatohepatitis. Lancet (2001) 358:893-894.
123. CALDWELL SH, HESPENHEIDE EE, REDICK JA, IEZZONI JC, BATTLE EH, SHEPPARD BL: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2001) 96:519-525.
124. HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Engl. J. Med. (2007) 357:28-38.
125. NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356:2457-2471.
126. NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, OLIVER D, BACON BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology (2003) 38:1008-1017.
127. PROMRAT K, LUTCHMAN G, UWAIFO GI et al.: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 39:188-196.
128. MOHANTY P, ALJADA A, GHANIM H et al.: Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. (2004) 89:2728-2735.
129. ENDO A: The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. (1992) 33:1569-1582.
130. KIYICI M, GULTEN M, GUREL S et al.: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. (2003) 17:713-718.
131. GEORGESCU EF, GEORGESCU M: Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all Agents Alike? results of a preliminary study. J. Gastrointestin. Liver Dis. (2007) 16:39-46.
132. RALLIDIS LS, DRAKOULIS CK, PARASI AS: Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis (2004) 174: 193-196.
133. CHALASANI N: Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology (2005) 41:690-695.
134. LAURIN J, LINDOR KD, CRIPPIN JS et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 23:1464-1467.
135. BASARANOGLU M, ACBAY O, SONSUZ A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. (1999) 31:384.
136. SAIBARA T, ONISHI S, OGAWA Y, YOSHIDA S, ENZAN H: Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet (1999) 353:1802.
137. RAO MS, PAPREDDY K, MUSUNURI S, OKONKWO A: Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor α ligand in rats. In vivo (2002) 16:145-152.
138. NAGASAWA T, INADA Y, NAKANO S et al.: Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. (2006) 536:182-191.
139. YESILOVA Z, YAMAN H, OKTENLI C et al.: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. (2005) 100:850-855.
140. GRATTAGLIANO I, VENDEMIALE G, CARACENI P et al.: Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J. Nutr. (2000) 130:2131-2136.
141. HASEGAWA T, YONEDA M, NAKAMURA K, MAKINO I, TERANO A: Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol. Ther. (2001) 15:1667-1672.
142. LAVINE JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr. (2000) 136:734-738.
143. HARRISON SA, TORGERSON S, HAYASHI P, WARD J, SCHENKER S: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2003) 98:2485-2490.
144. GUALLAR E, HANLEY DF, MILLER ER III: An editorial update: annus horribilis for vitamin E. Ann. Intern. Med. (2005) 143:143-145.
145. PAMUK GE, SONSUZ A: N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. (2003) 18: 1220-1221.
146. KANESHIRO Y, NAKANO H, KUMADA K et al.: Augmentation of mitochondrial reduced glutathione by S-adenosyl-L-methionine administration in ischemia-reperfusion injury of the rat steatotic liver induced by choline-methionine-deficient diet. Eur. Surg. Res. (1998) 30:34-42.
147. OSMAN E, OWEN JS, BURROUGHS AK: Review article: S-adenosyl-L-methionine - a new therapeutic agent in liver disease? Aliment. Pharmacol. Ther. (1993) 7:21-28.
148. MIGLIO F, ROVATI LC, SANTORO A, SETNIKAR I: Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung (2000) 50:722-727.
149. ABDELMALEK MF, ANGULO P, JORGENSEN RA, SYLVESTRE PB, LINDOR KD: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. (2001) 96:2711-2717.
150. DI SARIO A, BENDIA E, TAFFETANI S et al.: Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig. Liver Dis. (2005) 37:869-876.
151. FEDERICO A, TRAPPOLIERE M, TUCCILLO C et al.: A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut (2006) 55:901-902.
152. LOGUERCIO C, FEDERICO A, TRAPPOLIERE M et al.: The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a Pilot study. Dig. Dis. Sci. (2007).
153. NEUNER P, KLOSNER G, SCHAUER E et al.: Pentoxifylline in vivo down-regulates the release of IL-1 β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology (1994) 83:262-267.
154. WIGG AJ, ROBERTS-THOMSON IC, DYMOCK RB, MCCARTHY PJ, GROSE RH, CUMMINS AG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut (2001) 48:206-211.
155. ADAMS LA, ZEIN CO, ANGULO P, LINDOR KD: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2004) 99:2365-2368.
156. HEMPFLING W, DILGER K, BEUERS U: Systematic review: ursodeoxycholic acid - adverse effects and drug interactions. Aliment. Pharmacol. Ther. (2003) 18:963-972.
157. PORTINCASA P, VACCA M, MOSCHETTA A et al.: Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. (2005) 11:7-16.
158. PORTINCASA P, MOSCHETTA A, PETRUZZELLI M, PALASCIANO G, DI CIAULA A, PEZZOLLA A: Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract. Res. Clin. Gastroenterol. (2006) 20:1017-1029.
159. PORTINCASA P, MOSCHETTA A, PALASCIANO G: Cholesterol gallstone disease. Lancet (2006) 368:230-239.
160. PORTINCASA P, MOSCHETTA A, VAN ERPECUM KJ et al.: Pathways of cholesterol crystallization in model bile and native bile. Dig. Liver Dis. (2003) 35:118-126.
161. OKAN A, ASTARCIOGLU H, TANKURT E et al.: Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig. Dis. Sci. (2002) 47:2389-2397.
162. SANTOS VN, LANZONI VP, SZEJNFELD J, SHIGUEOKA D, PARISE ER: A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz. J. Med. Biol. Res. (2003) 36:723-729.
163. MENDEZ-SANCHEZ N, GONZALEZ V, CHAVEZ-TAPIA N, RAMOS MH, URIBE M: Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann. Hepatol. (2004) 3:108-112.
164. LINDOR KD, KOWDLEY KV, HEATHCOTE EJ et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 39:770-778.
165. ERSOZ G, GUNSAR F, KARASU Z, AKAY S, BATUR Y, AKARCA US: Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. (2005) 16:124-128.
166. DUFOUR JF, ONETA CM, GONVERS JJ et al.: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. (2006) 4:1537-1543.
167. VITALE C, MERCURO G, CASTIGLIONI C et al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. (2005) 4:6.
168. BATALLER R, SCHWABE RF, CHOI YH et al.: NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. (2003) 112:1383-1394.
169. YOSHIJI H, KURIYAMA S, YOSHII J et al.: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology (2001) 34:745-750.
170. RAMALHO LN, RAMALHO FS, ZUCOLOTO S et al.: Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology (2002) 49:1499-1502.
171. YOSHIJI H, YOSHII J, IKENAKA Y et al.: Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. (2002) 37:22-30.
172. KURTZ TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-γ activator. Acta Diabetol. (2005) 42(Suppl. 1):S9-S16.
173. YOKOHAMA S, YONEDA M, HANEDA M et al.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 40:1222-1225.
174. KOTEISH A, DIEHL AM: Animal models of steatosis. Semin. Liver Dis. (2001) 21:89-104.
175. COPE K, RISBY T, DIEHL AM: Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology (2000) 119:1340-1347.
176. NAIR S, COPE K, RISBY TH, DIEHL AM: Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2001) 96:1200-1204.
177. SOLGA SF, DIEHL AM: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J. Hepatol. (2003) 38:681-687.
178. LOGUERCIO C, DE SIMONE T, FEDERICO A et al.: Gut-liver axis: a new point of attack to treat chronic liver damage? Am. J. Gastroenterol. (2002) 97:2144-2146.
179. LI Z, YANG S, LIN H et al.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 37:343-350.
180. LOGUERCIO C, FEDERICO A, TUCCILLO C et al.: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. (2005) 39:540-543.
181. SOZA A, RIQUELME A, GONZALEZ R et al.: Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci. (2005) 50:1136-1140.
182. LEVY JR, CLORE JN, STEVENS W: Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology (2004) 39:608-616.
183. MURASE T, AOKI M, TOKIMITSU I: Supplementation with α-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of β-oxidation in Zucker fatty rats. Biochim. Biophys. Acta (2005) 1733:224-231.
184. ALWAYN IP, ANDERSSON C, ZAUSCHER B, GURA K, NOSE V, PUDER M: ω-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation (2005) 79:606-608.
185. ALWAYN IP, GURA K, NOSE V et al.: ω-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr. Res. (2005) 57:445-452.
186. BUANG Y, CHA JY, NAGAO K, WANG YM, INOUE N, YANAGITA T: Alleviation of fatty liver by α-linolenic acid. J. Nutr. Sci. Vitaminol. (Tokyo) (2004) 50:272-276.
187. PAWLOSKY RJ, SALEM N Jr: Development of alcoholic fatty liver and fibrosis in rhesus monkeys fed a low n-3 fatty acid diet. Alcohol Clin. Exp. Res. (2004) 28:1569-1576.
188. CAPANNI M, CALELLA F, BIAGINI MR et al.: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment. Pharmacol. Ther. (2006) 23:1143-1151.
189. MERAT S, MALEKZADEH R, SOHRABI MR et al.: Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J. Clin. Gastroenterol. (2003) 36:266-268.
190. MERAT S, MALEKZADEH R, SOHRABI MR et al.: Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J. Hepatol. (2003) 38:414-418.
191. CONTOS MJ, CALES W, STERLING RK et al.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. (2001) 7:363-373.
192. CORTEZ-PINTO H, DE MOURA MC, DAY CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. (2006) 44:197-208.
193. BROUGHAN TA, DOUZDJIAN V: Donor liver selection. The South-Eastern organ procurement foundation liver committee. Am. Surg. (1998) 64:785-790.
194. FRIEDMAN SL: Emerging therapies for hepatic fibrosis. UpToDate (2007) v.15.2:1-5.
195. GILAT T, LEIKIN-FRENKEL A, GOLDINER I, HALPERN Z, KONIKOFF FM: Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugate. Hepatology (2002) 35:597-600.
196. GILAT T, LEIKIN-FRENKEL A, GOLDINER I et al.: Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology (2003) 38:436-442.
197. HARA-CHIKUMA M, VERKMAN AS: Physiological roles of glycerol-transporting aquaporins: the aquaglyceroporins. Cell Mol. Life Sci. (2006) 63:1386-1392.
198. JEYASEELAN K, SEPRAMANIAM S, ARMUGAM A, WINTOUR EM: Aquaporins: a promising target for drug development. Expert Opin. Ther. Targets (2006) 10:889-909.
199. CHIAPPINI F, BARRIER A, SAFFROY R et al.: Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab. Invest. (2006) 86:154-165.
200. KISHIDA K, SHIMOMURA I, KONDO H et al.: Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel. J. Biol. Chem. (2001) 276:36251-36260.
201. MAEDAN, FUNAHASHI T, HIBUSE T et al.: Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc. Natl. Acad. Sci. USA (2004) 101:17801-17806.
202. HARA-CHIKUMA M, SOHARA E, RAI T et al.: Progressive adipocyte hypertrophy in aquaporin-7-deficient mice: adipocyte glycerol permeability as a novel regulator of fat accumulation. J. Biol. Chem. (2005) 280:15493-15496.
203. HIBUSE T, MAEDA N, FUNAHASHI T et al.: Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. Proc. Natl. Acad. Sci. USA (2005) 102:10993-10998.
204. MARRADES MP, MILAGRO FI, MARTINEZ JA, MORENO-ALIAGA MJ: Differential expression of aquaporin 7 in adipose tissue of lean and obese high fat consumers. Biochem. Biophys. Res. Commun. (2006) 339:785-789.
205. MATSUMURA K, CHANG BH, FUJIMYA M et al.: Aquaporin 7 is a {β} cell protein and regulator of intra-islet glycerol content and glycerol kinase activity, {β} cell mass, and insulin production and secretion. Mol. Cell Biol. (2007).
206. CARBREY JM, GORELICK-FELDMAN DA, KOZONO D et al.: Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver. Proc. Natl. Acad. Sci. USA (2003) 100:2945-2950.
207. ROJEK AM, SKOWRONSKI MT, FUCHTBAUER EM et al.: Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc. Natl. Acad. Sci. USA (2007) 104:3609-3614.
208. PATSOURIS D, MANDARD S, VOSHOL PJ et al.: PPARα governs glycerol metabolism. J. Clin. Invest. (2004) 114:94-103.
209. KISHIDA K, SHIMOMURA I, NISHIZAWA H et al.: Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor ω. J. Biol. Chem. (2001) 276:48572-48579.
210. KURIYAMA H, SHIMOMURA I, KISHIDA K et al.: Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes (2002) 51:2915-2921.
211. PORTINCASA P, MOSCHETTA A, MAZZONE A, PALASCIANO G, SVELTO M, CALAMITA G: Water handling and aquaporins in bile formation: recent advances and research trends. J. Hepatol. (2003) 39:864-874.
212. BEITZ E, SCHULTZ JE: The mammalian aquaporin water channel family: a promising new drug target. Curr. Med. Chem. (1999) 6:457-467.
213. MORISHITA Y, SAKUBE Y, SASAKI S, ISHIBASHI K: Molecular mechanisms and drug development in aquaporin water channel diseases: aquaporin superfamily (superaquaporins): expansion of aquaporins restricted to multicellular organisms. J. Pharmacol. Sci. (2004) 96:276-279.
214. WANG F, FENG XC, LI YM, YANG H, MA TH: Aquaporins as potential drug targets. Acta Pharmacol. Sin. (2006) 27:395-401.
215. VERKMAN AS: More than just water channels: unexpected cellular roles of aquaporins. J. Cell Sci. (2005) 118:3225-3232.
216. FASSHAUER M, KLEIN J, LOSSNER U, KLIER M, KRALISCH S, PASCHKE R: Suppression of aquaporin adipose gene expression by isoproterenol, TNF-α, and dexamethasone. Horm. Metab. Res. (2003) 35:222-227.
217. FRUHBECK G, CATALAN V, GOMEZ-AMBROSI J, RODRIGUEZ A: Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol. Sci. (2006) 27:345-347.
218. RAZANI B, COMBS TP, WANG XB et al.: Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. (2002) 277:8635-8647.
219. FERNANDEZ MA, ALBOR C, INGELMO-TORRES M et al.: Caveolin-1 is essential for liver regeneration. Science (2006) 313:1628-1632.
220. CANBAY A, BECHMANN L, GERKEN G: Lipid metabolism in the liver. Z. Gastroenterol. (2007) 45:35-41.
221. FRANK PG, LISANTI MP: Caveolin-1 and liver regeneration: role in proliferation and lipogenesis. Cell Cycle (2007) 6:115-116.
222. TENENBAUM A, MOTRO M, FISMAN EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. (2005) 4:14.
223. PRUDENTE S, FLEX E, MORINI E et al.: A functional variant of the adipocyte glycerol channel aquaporin 7 gene is associated with obesity and related metabolic abnormalities. Diabetes (2007) 56:1468-1474.
224. CAI D, YUAN M, FRANTZ DF et al.: Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. (2005) 11:183-190.
225. ADAMS LA, LYMP JF, ST SAUVER J, et al.: The natural histoty of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 129:113-121.
226. PETRICOIN E, WULFKUHLE J, ESPINA V, LIOTTA LA: Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J. Proteome Res. (2004) 3:209-217.
227. CALLEWAERT N, VAN VH, VAN HA, LAROY W, DELANGHE J, CONTRERAS R: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. (2004) 10:429-434.
228. KALAANY NY, MANGELSDORF DJ: LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. (2006) 68:159-191.
229. MODICA S, MOSCHETTA A: Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. (2006) 580:5492-5499.
230. BOOKOUT AL, JEONG Y, DOWNES M, YU RT, EVANS RM, MANGELSDORF DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell (2006) 126:789-799.
231. YKI-JARVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
232. SAM S, DUNAIF A: Polycystic ovary syndrome: syndrome XX? Trends Endocrinol. Metab. (2003) 14:365-370.
233. GRUNDY SM: Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am. J. Clin. Nutr. (2004) 80:1-2.
234. YAKARYILMAZ F, GULITER S, SAVAS B et al.: Effects of vitamin E treatment on peroxisome proliferator-activated receptor-α expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern. Med J. (2007) 37:229-235.
235. CARACENI P, DOMENICALI M, MARIA PERTOSA A et al.: The nutritional status modulates preservation-reperfusion injury in rat fatty liver. J. Surg. Res. (2005) 127:190-196.